Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenyl Propionic Acid SCHEMBL28549079 | 0.91 | RAB9A (0.60) | HDAC1HDAC6MTNR1AMTNR1BRAB9A | |
| SCHEMBL28262492 | 0.90 | HDAC1 (0.66) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| Phenyl Propionic Acid SCHEMBL28910944 | 0.90 | RAB9A (0.59) | HDAC1HDAC6MTNR1AMTNR1BRAB9A | |
| SCHEMBL12698686 | 0.89 | HDAC1 (0.72) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL3145595 | 0.88 | HDAC1 (0.75) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL7332474 | 0.86 | TAAR1 (0.61) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL22070746 | 0.86 | SMPD1 (0.60) | RAB9A | |
| SCHEMBL4644508 | 0.86 | SIRT2 (0.48) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL1802183 | 0.86 | ALDH1A1 (0.56) | HDAC1HDAC6MTNR1AMTNR1BTAAR1 | |
| SCHEMBL9804265 | 0.86 | FFAR1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111689855-A | Method for improving conversion rate of preparing methyl cinnamate | 李德祥 | 2020-09-22 | — | — | CN | claimed |
| WO-2002015691-A1 | USE FOR CONIFER SAPLING PROTECTION AGAINST INSECT ATTACK | ROBIGUS AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021032218-A1 | HETEROCYCLIC THR-β RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR | 苏州闻天医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-0874829-A1 | AMINO ACID DERIVATIVES, THE PREPARATION AND USE THEREOF AS ENDOTHELIN ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997012878-A1 | AMINO ACID DERIVATIVES, THE PREPARATION AND USE THEREOF AS ENDOTHELIN ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-10 | — | — | WO | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| US-4177197-A | Cyclization substrates and 7α-substituted 19-norsteroid derivatives | AKZONA INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4117234-A | DERIVATIVES OF 2-(6-PHENYLHEX-3-ENYL)-CYCLOPENT-2-EN-1-OL | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | HDAC1 1404/4885HDAC6 483/4885MTNR1A 2086/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | HDAC1 878/4885HDAC6 427/4885MTNR1A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.